^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Gallbladder Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers
Excerpt:
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers….The three approvals authorise Lynparza for:...maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
Source:
Title:
88P - Efficacy of olaparib in advanced cancers occurring in patients with germline or somatic tumor mutations in homologous recombination (HR) genes, a Belgian Precision phase II basket study
Published date:
09/13/2021
Excerpt:
Six partial responses occurred...a BRCA1 gallbladder cancer...Treatment with olaparib shows activity in cancer pts with a HR gene mutation and is well tolerated.
Trial ID:
Source:
Title:
Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study
Published date:
10/16/2023
Excerpt:
In summary, the BRCA1 cohort includes 9 patients with pancreatic cancer and 18 patients with other tumor types. As far as the size of the cohorts allows, the CBR appears to be similar between the two groups: 55.5% (2 PR and 3 SD) for the pancreatic cancer patients and 66.6% (1 PR and 11 SD) for the other cancer patients. The partial remission was in a patient with gallbladder cancer, out of six patients with this cancer included in the study....In BRCA1/2-mutated cancers, olaparib can be active and produce durable responses in various cancer types.
Trial ID:
